Physician profile
Michael T Kidd
NPI 1093940736
$506.88
in general payments reported to CMS, 2019-2025
15 companies · $69.26 in 2025
The $69.26 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2021: $73.81 · 2022: $40.13 · 2023: $125 · 2024: $62.89 · 2025: $69.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $140 · Food and Beverage: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $139.82 |
| Food and Beverage | $117.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $133.22 | 2019-2023 | Rybrevant |
| Novartis Pharmaceuticals Corporation | $109.11 | 2019-2024 | |
| Amgen INC. | $66.92 | 2019-2022 | |
| Pinnacle Biologics, INC | $49.81 | 2025 | Photofrin |
| E.R. Squibb & Sons, L.L.C. | $28.83 | 2023 | Sprycel |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Merck Sharp & Dohme LLC | $19.45 | 2025 | Lynparza, Keytruda |
| Acrotech Biopharma INC. | $17.41 | 2024 | Beleodaq |
| Daiichi Sankyo INC. | $16.24 | 2021 | |
| Pfizer INC. | $15.50 | 2021 | |
| Aveo Pharmaceuticals, INC. | $15.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.39 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kidd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.